YC-1 [3-~5'-hydroxymethyl-2'-furyl)-l-benzylindazolel inhibited the aggregation of and ATP release from washed rabbit platelets induced by arachidonic acid (AA), collagen, U46619, platelet-activating factor (PAF), and thrombin in a concentration-dependent manner. YC-1 also disaggregated the clumped platelets caused by these inducers. The thromboxane formation caused by collagen, PAF, and thrombin was inhibited by concentrations of YC-1 that did not affect formation of thromboxane B2 and prostaglandin D2 caused by AA. YC-1 suppressed the increase of intracellular Ca2+ concentration and generation of inositol 1,4,5-trisphosphate caused by these five aggregation inducers. Both the cAMP and cGMP contents of platelets were increased by YC-1 in a concentration-and time-dependent manner. Like sodium nitroprusside, YC-1 potentiated formation of cAMP caused LATELETS AND platelet-derived vasoactive agents are important physiologic regulators of vascular tone and hemostasis. Much evidence indicates that interactions between platelet and vessel wall contribute significantly to the pathogenesis of atherosclerosis, myocardial infarction, unstable angina pectoris, and thrombosis.'-4 Platelets are activated by diverse stimuli in vivo, including diseased arteries.' Mural thrombus formation can restrict the flow of blood to vital tissues or organs leading to peripheral, cerebral, or coronary ischemia. The developing thrombus may embolize with potentially lethal consequences. Activation of platelets may lead to not only acute vascular complications such as thrombosis but also, perhaps due to the release of growth factors, to enduring effects such as smooth muscle proliferation, one of the hallmarks of ather~sclerosis.',~ Therefore, inhibition of platelet function may be a promising approach to prevent and to treat diseases in which a pathophysiologic participation of activated platelets appears likely.
by prostaglandin E, but not that by 3-isobutyl-l-methylxanthine. Adenylate cyclase and cAMP phosphodiesterase activities were not altered by YC-1. Activity of cGMP phosphodiesterase was unaffected by YC-1. Activities of guanylate cyclase in platelet homogenate and cytosolic fraction were activated by YC-1, whereas particulate guanylate cyclase activity was unaffected. The antiplatelet effect of sodium nitroprusside but not that of YC-1 was blocked by hemoglobin and potentiated by superoxide dismutase. After intraperitoneal administration for 30 minutes, YC-1 prolonged the tail bleeding time of conscious mice. These data indicate that YC-1 is a direct soluble guanylate cyclase activator in rabbit platelets. It may also possess antithrombotic potential in vivo. 0 1994 by The American Society of Hematology.
proteins mediated by either cAMP/cAMP-dependent protein kinase (PKA) or cGMP/cGMP-dependent protein kinase (PKG), respectively. The platelet pathways affected by both cAMP/PKA and cCMPPKG result in the inhibition of platelet activation, most likely caused by the inhibition of agonistinduced calcium mobilization. There is also evidence that cAMP and cGMP can suppress platelet reactions in vivo, indicating that an antiplatelet action may supplement their effects on vascular smooth muscle in the treatment of cardiovascular disease^.^^"'
We found that YC-1, a chemically synthetic benzylindazole compound, possessed antiplatelet activity. In the present report, we endeavored to elucidate the mechanism of its inhibitory activity on platelet aggregation and proved it to be a novel soluble guanylate cyclase activator in platelets.
MATERIALS AND METHODS
Platelet aggregation und ATP release reaction. Blood was collected from the rabbit marginal ear vein and mixed with EDTA to a final concentration 6 mmol/L. It was centrifuged for 10 minutes at 90s and room temperature, and the supernatant was obtained as platelet-rich plasma (PRP). Platelet suspension was prepared from EDTA-anticoagulated PRP according to washing procedures described previously." Platelets were counted by Hemalaser 2 (Sebia, Molineaux, France) and adjusted to a concentration 3 X IO8 platelets/ mL. Platelet pellets were finally suspended in Tyrode's solution of the following composition in millimoles per liter: NaCl(136.8), KC1 (2.8), NaHCO, (1 1 .g), MgCI2 (2.1), NaH2P0, (0.33), CaCI, (1.0). and glucose (1 I .2) containing bovine serum albumin (0.35%). Aggregation was measured at 37°C by turbidimetry as described by 0'Brien.l' ATP released from platelets was detected by the bioluminescence method of DeLuca and McElory." Both aggregation and ATP release were simultaneously measured in a Lumi-aggregometer (Chrono-Log CO, Havertown, PA) connected to two dual-channel recorders. Platelet preparations were stirred at 1,200 rpm. To eliminate the effect of solvent on aggregation, the final concentration of dimethyl sulfoxide (DMSO) was fixed at 0.5% (vol/vol).
Tromboxane BZ andprostaglandin D2 assay. After 6 minutes of platelet incubation with the inducer, EDTA (2 mmoliL) and indomethacin (SO pnol/L) were added to halt thromboxane and prostaglandin Dz formation. After centrifugation in an Eppendorf microcentrifuge (Model 541SC; Eppendorf, Hamburg, Germany) for 2 minutes, thromboxane B, and prostaglandin D, in the supernatant were assayed by enzyme immunoassay. For personal use only. on January 1, 2018. by guest www.bloodjournal.org From lets (10' platelets/mL, 500 pL) prepared as described above were incubated with DMSO (0.5%), YC-I, or prostaglandin E, at 37°C for 3 minutes and then stimulated with the aggregation inducers. The reactions were terminated by the addition of 100 pL of ice-cold perchloric acid (20%) followed by 20 minutes of incubation in an ice bath. After centrifugation at 2,OOOg for 15 minutes at 4°C the supernatant was recovered and its pH was adjusted to 7.5 with a 10 N KOH solution. KCIO4 was precipitated for 30 minutes at 4°C and sedimented at 2,OOOg for 15 minutes at 4°C. The amount of IP, in the resulting supernatant was determined by radioimmunoassay (RIA).
Measurement of intracellular calcium in platelets. The method of Pollock and RinkI4 was followed. Platelets (3 X 10' platelets/ mL) were incubated with fura-2IAM (5 pmoVL) at 37°C for 45 minutes and centrifuged at 500g; the resultant pellet was washed with Tyrode solution containing 1 mmol/L EDTA. After centrifugation, platelets were resuspended in the Tyrode solution containing Ca'+ (1 mmol/L). Fluorescence (Ex 339 nm, Em 500 nm) was measured with a Hitachi Fluorescence Spectrophotometer (Model F4000; Hitachi, Tokyo, Japan) at 37°C. At the end of the experiment, the cells were treated with Triton X-l00 (0.1 %) followed by the addition of EGTA (1 0 mmoI/L) to obtain the maximal and minimal fluorescence, respectively. [Ca"], was calculated as described for fura-2 using Ca2+-dye dissociation constant 224 nmol/L."
Estimation of platelet cyclic nucleotides. The method of Kamiguian et all6 was used. The platelet suspension was warmed at 37°C for 1 minute in an aggregometer (Chrono-Log CO) stirred at 1,200 rpm. YC-1, prostaglandin E , , sodium nitroprusside, or 3-isobutyll-methylxanthine (IBMX) was then added with incubation for various time intervals. The reaction was stopped by adding EDTA (IO mmol/L) followed immediately by boiling for 5 minutes. Upon cooling to 4"C, precipitated protein was sedimented by centrifugation in an Eppendorf microcentrifuge (Model 5415 C). The supernatant was used to assay for cyclic AMP and cyclic GMP by enzyme immunoassay kit.
Phosphodiesterase assay. The method of Moore et all' was used. Washed rabbit platelets prepared as described above were resuspended in 50 mmoVL Tris-HCI (pH 7.4, containing 5 mmoVL MgCI'). Platelets were disrupted by sonication at 4°C (4 to 6 X I O seconds; setting 5; Vibra cell; Sonics and Materials Inc, Danbury, CT). The lysate was centrifuged at 39,OOOg for 20 minutes (4°C). The supernatant contained greater than 95% cyclic nucleotide phosphodiesterase activity.
The crude cytosolic enzyme (1 mg/mL; 0.1 mL) was incubated with Tris-HCI (0.2 mL) at 37°C for 5 minutes; 0.1 mL cAMP (final concentration, 0.25 pmoVL containing 0.1 pCi ['HICAMP) or cGMP (final concentration, 0.25 pmol/L containing 0.1 pCi [,H]cGMP) was then added. After 30 minutes at 37°C the samples were heated to 100°C for 1 minute before cooling. Ophiophagus hannah snake venom ( I mg/mL; 0.1 mL) was then added and incubated at 25°C for 30 minutes to convert the 5'-AMP or 5'-GMP to the uncharged nucleosides, adenosine, or guanosine. An ion-exchange resin slurry (1.0 m L ; Dowex-l; Sigma Chemical CO, St Louis, MO) was added to bind all unconverted cAMP and cGMP. After centrifuging, an aliquot (0.5 mL) of the supernatant was removed for determination in a liquid scintillation counter.
Guanylate cyclase assay. Washed rabbit platelets were prepared as above but resuspended in Tris-HCI buffer (50 mmoVL; pH 7.4). Platelets were disrupted by sonication as described above and the lysate was centrifuged at 39,OOOg at 4°C for 20 minutes. The supernatant fluid was used as a source of soluble guanylate cyclase. The pellet was washed twice in the original amount of Tris-HC1 buffer and used as membrane guanylate cyclase. Protein content was determined with a protein assay kit (BioRad, Richmond, CA) and adjusted to a concentration 1 mg/mL. GTP and cGMP were separated on neutral alumina as described by White and Zenser" and the radioactivity (["PIcGMP) was determined in a liquid scintillation counter.
Adenylate cyclase assay. Rabbit platelet membrane prepared as described above was finally resuspended in Tris-HCI buffer (50 mmoVL, pH 7.4) containing EDTA (5 mmoVL). Adenylate cyclase activity was measured as described by Insel et al.'' Membranes (20 pL) were incubated in a final volume (60 pL) with other reactants as follows (final concentrations): Tris-HCI, 50 mmoVL (pH 7.4); EDTA, 2.6 mmoVL; MgClz, 13 mmoVL; creatine phosphate, 25 mmoVL; creatine phosphokinase, 1 mg/mL; CAMP, 1 mmol/L; ATP, 0.5 mmoVL containing 1 X lo6 cpm [cY-"P]ATP; and other additions as indicated in the text. The reaction was initiated by adding platelet protein and was performed at 30°C for 20 minutes. The reaction was terminated by adding HCI (0.5 N. 0.2 mL) and boiling the sample for 6 minutes. After cooling in an ice bath, imidazole (1 mmoVL, 200 pL) was added. ATP and cAMP were separated on neutral alumina as previously described" and [32P]cAMP was determined with a liquid scintillation counter.
Tail bleeding time in conscious mice. Thirty minutes after the intraperitoneal administration of DMSO (2.5 pWg), YC-I, or indomethacin, male mice (18 to 22 g) were placed in a tube holder with the tail allowed to protrude. The tail was transected at 2 mm from the tip and 1.5 cm of the distal portion was vertically immersed into saline at 37°C. The bleeding time was then measured as described by Hornstra et al."
Materials. YC-I [3-(5'-hydroxymethyl-2'-furyl)-l-benzylindazole; Fig l ] was chemically synthesized as described previously.'' Bovine thrombin (Parke Davis CO, Detroit, MI) was dissolved in glycerol (50% vol/vol) for a stock solution of 100 NIH U/mL. Collagen (type I, bovine Achilles tendon; Sigma) was homogenized in acetic acid (25 mmol/L) and stored (1 mg/mL) at -70°C. Plateletactivating factor (PAR I-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; Sigma) was dissolved in chloroform and diluted into 0. Protein assay kit and neutral alumina were obtained from BioRad.
RESULTS
Effects of YC-l on aggregation and ATP release of washed rabbit platelets. In washed rabbit platelets, U46619 (1 pmoVL), collagen (10 pg/mL), AA (100 pmoVL), PAF (3.6 nmoVL), and thrombin (0.1 U/mL) all caused approximately 90% aggregation. YC-1 inhibited U46619-, collagen-, (Fig 2) . PGE, (1 pmoVL) also inhibited completely platelet aggregation caused by these aggregation inducers. In contrast, sodium nitroprusside (10 pmol/L) inhibited U46619-, AA-, and collagen-induced platelet aggregation by 100.0% f O.O%, 45.1 t-4.0%, and 46.9% ? 5.4% (n = 6), but did not significantly affect PAF-and thrombininduced maximal platelet aggregation even when the concentration 1 mmol/L was used (6.7% 2 1.4% and 7.4% ? 1.1% inhibition, respectively; n = 6). However, sodium nitroprusside (1 mmoVL) slowed the aggregation induced by PAF and thrombin. It prolonged the latent periods of PAF-and thrombin-induced platelet aggregation from 0.10 f 0.02 and 0.28 t 0.04 minutes to 0.25 ? 0.02 and 0.55 ? 0.04 minutes (n = 6), respectively. It also induced a more rapid recovery of PAF-and thrombin-induced aggregation (data not shown).
YC-1, PGE, , and sodium nitroprusside, at concentrations that maximally inhibited platelet aggregation, also markedly disaggregated platelets that had been previously aggregated with these five inducers. Again, sodium nitroprusside was less potent than YC-1 and PGE, in disaggregating platelets (see Fig 3 for PAF-induced platelet aggregation) .
YC-I (1 .S to 1.50 pmoVL), PGE, (1 pmol/L), and sodium nitroprusside (10 pmol/L) also inhibited, in a concentrationdependent manner, the ATP release caused by these five inducers. Inhibition of ATP release was parallel to inhibition of platelet aggregation (data not shown). However, YC-I (1.50 pmol/L), PGE, (1 and 10 pmoVL), and sodium nitroprusside (1 mmoVL) did not affect the platelet shape change For caused by these five inducers even when the aggregation and ATP release were blocked completely (data not shown).
Effects of YC-1 on platelet thromboxane B2 and prostaglandin D2 formation. The thromboxane B2 level of resting platelets was 0.6 ? 0.2 ng/3 X lo8 platelets. AA, collagen, PAF, and thrombin markedly increased, whereas U46619 insignificantly affected, the thromboxane B2 level after incubation with platelets for 6 minutes. Although YC-1 inhibited collagen-, PAF-, and thrombin-induced thromboxane B2 formation in a concentration-dependent manner, it did not affect AA-induced thromboxane B2 formation at a concentration (30 pmoVL) that inhibited more than 70% of the aggregation induced by AA. However, YC-1 at a concentration (60 pmoV L) that completely blocked AA-induced platelet aggregation partially suppressed AA-induced thromboxane B2 formation (Table 1) . Similarly, PGE, and sodium nitroprusside markedly suppressed collagen-, PAF-, and thrombin-induced thromboxane B2 formation without affecting that formation caused by AA (Table 1 ). In contrast, indomethacin (1 pmoV L) and imidazole (1 mmol/L) markedly inhibited AA-induced thromboxane B2 formation (Table 1) .
The prostaglandin D2 level of resting platelets (0.07 t 0.01 ng/3 X lo8 platelets) was increased in the presence of AA (100 pmol/L) to 1.32 t 0.20 ng/3 X lo8 platelets. This prostaglandin D2 formation was inhibited by indomethacin, but was enhanced markedly by imidazole. YC-l (60 pmoVL) did not inhibit this AA-induced prostaglandin D2 formation ( Table 2) .
Effects of YC-1 on IP3 formation. Resting platelets containing 0.9 t 0.1 pmol of IPJ109 cells. AA (100 pmol/L), U46619 (1 pmoVL), PAF (3.6 nmol/L), and thrombin (0.1 U/mL) induced a rapid and transient formation of IP3, reaching its peak within 5 seconds. Collagen (10 pg/mL) also caused IP3 formation of platelets with a slower rate, reaching its peak within 30 seconds. The maximum production of IP3 at 5 seconds after AA, U46619, PAF, and thrombin stimulation was 3.4 2 0.3, 3.4 t 0.4, 3.8 2 0.3, and 4.1 5 0.7 pmoVlO' platelets, respectively, whereas the maximum production of IP3 at 30 seconds after collagen stimulation was 3.9 -+ 0.5 pmoVlO' platelets. YC-1 (60 or 300 pmol/L) and PGE, (1 pmol/L) at concentrations that markedly inhibited platelet aggregation also suppressed the IP3 formation caused by these five inducers (Fig 4) .
Effects of YC-I on the intracellular calcium of platelets. In fura-2-loaded platelets, AA, U46619, collagen, PAF, and thrombin caused an increase of intracellular free calcium. As shown in Fig 5, this increase caused by these five inducers was almost completely inhibited by YC-1 (60 pmol/L).
Effects of YC-I on the platelet CAMP and cGMP levels. The CAMP and cGMP levels of resting platelets were 2.1 2 0.3 and 1.2 2 0.1 pmoVlO' platelets, respectively. YC-l (15 to 300 pmoVL) increased both levels in a concentrationand time-dependent manner (Fig 6) . After incubation with platelets for 45 seconds, YC-1 (300 pmoVL) increased the cAMP and cGMP levels to 40.2 t 10.5 and 117.2 t 44.8 pmol/109 platelets, respectively. The cGMP level was increased rapidly and reached a maximum at 15 seconds that was maintained for 2 minutes after incubation of YC-l with platelets. In contrast, YC-1 increased the cAMP level much more slowly than it increased the cGMP level and attained no maximal level within 2 minutes (Fig 6) (Table  3) . Effects of YC-1 on platelet phosphodiesterase. As shown in Table 4 , IBMX inhibited platelet cAMP and cGMP phosphodiesterases in a concentration-dependent manner. Inhibition of cAMP phosphodiesterase was more pronounced than inhibition of cGMP phosphodiesterase. YC-l (30 to 300 pmol/L,) did not inhibit activities of cAMP and cGMP phosphodiesterase in platelets.
Effects of YC-I on platelet adenylate cyclase and guanylate cyclase activities. Adenylate cyclase activity of resting platelets was 5.1 t 0.9 pmol cAMP formedmg proteidmin. PGE, (1 pmoVL) and forskolin (10 pmoVL) increased this basal activity to 47.1 t 4.0 and 72.3 t 8.1 pmol cAMP formed/mg proteidmin, respectively. However, YC-l (60 to 300 pmoVL) did not affect the platelet adenylate cyclase activity ( Table 5) .
Guanylate cyclase activities of platelet lysate and the soluble fraction were 28.2 2 6.3 and 15.1 t 3.3 pmol cGMP formedhg proteidmin. YC-1 (6 to 150 pmoUL) and sodium nitroprusside (10 and 100 pmol/L.) increased the activities of guanylate cyclase of platelet lysate and soluble fraction in a concentration-dependent manner (Table 5) . However, YC-1 (150 pmol/L) and sodium nitroprusside (10 and 100 pmol/L) did not increase the platelet particulate guanylate cyclase activity (data not shown).
Effects of methemoglobin and superoxide dismutase on the antiplutelet activity of YC-I. YC-l (60 pmol/L) and sodium nitroprusside (10 pmolk) inhibited collagen ( For YC-1 (6 pmol/L) and sodium nitroprusside (1 pmoVL) inhibited collagen (10 pg/mL)-induced platelet aggregation 13.7% 2 2.4% and 17.8% 2 2.8% (n = 3 , respectively.
Superoxide dismutase (20 U/mL) did not affect this aggregation, but it potentiated the antiplatelet activity of sodium nitroprusside (66.4% 2 1.3% inhibition, n = 5) without affecting that of YC-l (18.9% % 3.9% inhibition, n = 5).
Effects of YC-I on tail bleeding time of mice. Tail bleeding time of untreated mice was 66.3 % 3.5 seconds (n = 8).
DMSO (2.5 p u g ) alone had no effect on (78.1 ? 5.5 seconds, n = lo), whereas indomethacin (3 mgkg) markedly prolonged, the tail bleeding time of mice (499.0 2 53.4 seconds, n = 10). YC-1 (3, 10, and 30 mg/kg) also markedly and significantly prolonged the tail bleeding time of mice to Phosphodiesterase activity was measured as described in Materials * P < .01 as compared with the basal activity. t P < ,001 as compared with the basal activity. * P < .05 as compared with the basal activity. For personal use only. on January 1, 2018. by guest www.bloodjournal.org From and concentration-dependent manner. However, YC-1 at a concentration 30 pmoVL inhibited more than 70% platelet aggregation induced by AA but did not affect AA-induced thromboxane BZ formation. Additionally, YC-1 also did not inhibit AA-induced prostaglandin D, formation. Thus, YC-1 inhibits collagen-, PAF-, and thrombin-induced thromboxane B2 formation via a step before cyclooxygenase. Phosphoinositide breakdown is an important pathway in signal transduction of agonist-induced platelet a c t i~a t i o n .~~.~~ This process generates two active products, diacylglycerol and inositol trisphosphate. The latter triggers calcium mobilization from intracellular compartments.26 The increase of intracellular Ca2' is very important for both the release reaction and activation of phospholipase Az, which is a rate-limiting enzyme for the generation of AA. YC-I inhibited collagen-, PAF-, and thrombin-induced increase of platelet intracellular free calcium concentration and IP, formation. Thus, YC-l inhibition of collagen-, PAF-, and thrombin-induced thromboxane Bz formation may be caused by its inhibition on phosphoinositide breakdown and increase of intracellular calcium concentration induced by these three inducers.
Elevation of cAMP and cGMP levels, either by stimulation of adenylate or guanylate cyclase or by inhibition of phosphodiesterases, are two of the most potent mechanisms of platelet Elevated CAMP and cGMP levels inhibit most platelet responses, including aggregation, ATP release, and increase of intracellular Ca2' concentration. YC-1 elevated platelet cGMP levels and increased the activities of guanylate cyclase of platelet lysate and soluble fraction without affecting particulate guanylate cyclase and cGMPphosphodiesterase activities. These data indicate that YC-I is an activator of platelet soluble guanylate cyclase. Nitrovasodilators, such as sodium nitroprusside and nitroglycerin, are believed to exert their effects via the release of nitric oxide, which stimulates the formation of cGMP by soluble guanylate ~yc1ase.z~ In biologic systems, superoxide dismutase extends the half-life of nitric oxide; therefore, superoxide dismutase may promote the effectiveness of nitric oxide by bringing it to its active biologic form." In contrast. methylene blue inhibits activation of soluble guanylate cyclase by nitric oxide and hemoglobin chelates nitric oxide.x The antiplatelet activity of sodium nitroprusside was inhibited by hemoglobin and potentiated by superoxide dismutase, respectively. However, the antiplatelet activity of YC-1 was affected by neither hemoglobin nor superoxide dismutase. Thus, YC-l may directly activate platelet soluble guanylate cyclase without causing release of nitric oxide.
YC-I and sodium nitroprusside also elevated platelet cAMP level. However, YC-I neither activated platelet adenylate cyclase nor inhibited platelet CAMP-phosphodiesterase activities. It has been reported by Maurice and Haslam'y that cGMP exerts important functional effects through a cGMP-inhibited low Km cAMP phosphodiesterase, an enzyme known to be present in many cells, including platelets. The nitrovasodilator sodium nitroprusside causes small increases in cAMP in rabbit platelets, in addition to the expected large increases in &MP. In our results, platelet cAMP levels increased by YC-1 and sodium nitroprusside were not potentiated by IBMX, a nonselective phosphodiesterase inhibitor. In addition, YC-I , sodium nitroprusside, and IBMX potentiated cAMP formation caused by PGE, . Thus, elevation of platelet cAMP level by YC-l may be mediated by inhibition of cGMP-inhibited low Km cAMP phosphodiesterase.
In conclusion, YC-l is a direct activator of platelet soluble guanylate cyclase. It may also possess antithrombotic potential in vivo because the tail bleeding times of conscious mice were prolonged. However, further investigation of its in vivo antithrombogenic activity is warranted.
